RGEN Quote, Financials, Valuation and Earnings

InfuSystems Holdings has a net margin of -0.42% compared to Repligen's net margin of 5.12%. Repligen's return on equity of -0.41% beat InfuSystems Holdings's return on equity of 2.8%.

Repligen has a consensus price target of $190.31, signalling upside risk potential of 23.64%. On the other hand InfuSystems Holdings has an analysts' consensus of $14.13 which suggests that it could grow by 87.33%. Given that InfuSystems Holdings has higher upside potential than Repligen, analysts believe InfuSystems Holdings is more attractive than Repligen.

Repligen has a beta of 0.969, which suggesting that the stock is 3.075% less volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.531, suggesting its more volatile than the S&P 500 by 53.098%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

Repligen quarterly revenues are $154.9M, which are larger than InfuSystems Holdings quarterly revenues of $35.3M. Repligen's net income of -$654K is lower than InfuSystems Holdings's net income of $1.8M. Notably, Repligen's price-to-earnings ratio is 633.44x while InfuSystems Holdings's PE ratio is 119.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 13.74x versus 1.23x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -0.42% compared to Repligen's net margin of -18.58%. Repligen's return on equity of -0.41% beat Retractable Technologies's return on equity of -16.83%.

Repligen has a consensus price target of $190.31, signalling upside risk potential of 23.64%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Repligen has higher upside potential than Retractable Technologies, analysts believe Repligen is more attractive than Retractable Technologies.

Repligen has a beta of 0.969, which suggesting that the stock is 3.075% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.939, suggesting its more volatile than the S&P 500 by 93.884%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

Repligen quarterly revenues are $154.9M, which are larger than Retractable Technologies quarterly revenues of $10.3M. Repligen's net income of -$654K is higher than Retractable Technologies's net income of -$1.9M. Notably, Repligen's price-to-earnings ratio is 633.44x while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 13.74x versus 0.58x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -0.42% compared to Repligen's net margin of -4291.67%. Repligen's return on equity of -0.41% beat Catheter Precision's return on equity of -65.84%.

Repligen has a consensus price target of $190.31, signalling upside risk potential of 23.64%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 275.16%. Given that Catheter Precision has higher upside potential than Repligen, analysts believe Catheter Precision is more attractive than Repligen.

Repligen has a beta of 0.969, which suggesting that the stock is 3.075% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.184, suggesting its less volatile than the S&P 500 by 118.441%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Repligen quarterly revenues are $154.9M, which are larger than Catheter Precision quarterly revenues of $96K. Repligen's net income of -$654K is higher than Catheter Precision's net income of -$4.1M. Notably, Repligen's price-to-earnings ratio is 633.44x while Catheter Precision's PE ratio is 0.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 13.74x versus 1.42x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -0.42% compared to Repligen's net margin of -17.98%. Repligen's return on equity of -0.41% beat Xtant Medical Holdings's return on equity of -35.98%.

Repligen has a consensus price target of $190.31, signalling upside risk potential of 23.64%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 351.1%. Given that Xtant Medical Holdings has higher upside potential than Repligen, analysts believe Xtant Medical Holdings is more attractive than Repligen.

Repligen has a beta of 0.969, which suggesting that the stock is 3.075% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.673%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Repligen quarterly revenues are $154.9M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. Repligen's net income of -$654K is higher than Xtant Medical Holdings's net income of -$5M. Notably, Repligen's price-to-earnings ratio is 633.44x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 13.74x versus 0.58x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.